Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides (NCT05357794)

🧪 Interventions in This Study

• Brentuximab vedotin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (713) 563-2406

Email: bdabaja@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Mycosis Fungoides

• Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome — Basking Ridge, New Jersey
• Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome — St Louis, Missouri
• A Study of VG712 in Patients With Mycosis Fungoides — Tampa, Florida
• A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides — Baltimore, Maryland
• ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome — Duarte, California
• Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides — Chicago, Illinois

Explore by condition: All Mycosis Fungoides clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.